AnaptysBio, Inc. (NASDAQ:ANAB) Receives $35.11 Average Price Target from Brokerages

As of March 25, 2025, AnaptysBio, Inc. (NASDAQ:ANAB) has gathered a consensus rating of "Moderate Buy" from a group of eleven brokerage firms monitoring the stock, according to MarketBeat. This rating reflects the varying perspectives among analysts, where four have recommended holding the stock, six rated it as a buy, and one offered a strong buy sentiment. The average price target set by these analysts for AnaptysBio over the next 12 months is $35.11.

Recently, multiple research firms have provided updates on AnaptysBio. For instance, JPMorgan Chase & Co. increased their target price for the shares from $36.00 to $42.00 and assigned an “overweight” rating on March 5th. Meanwhile, HC Wainwright reaffirmed a “neutral” rating with a price target of $22.00 on March 4th. Truist Financial, on the other hand, revised their target price down from $30.00 to $20.00 while maintaining a “hold” position in their report issued on December 18th. In a more positive light, Wedbush retained an “outperform” rating with a target price of $40.00 in their report on February 12th, and Wells Fargo & Company set an even higher target of $51.00 while upgrading their rating to “overweight” on February 13th.

Performance Overview of AnaptysBio Stock

On Friday, AnaptysBio stock opened at $18.71. The company has a market capitalization of approximately $573.78 million, with a PE ratio of -3.08 and a beta of 0.02. Over the past year, the stock has seen a low of $12.21 and a high of $41.31. Currently, the fifty-day and two-hundred-day moving averages stand at $16.88 and $22.34, respectively.

In its most recent quarterly earnings report released on February 27th, the company reported an earnings loss of ($0.72) per share, beating analysts' expectations which had projected a loss of ($1.61). The company showed a staggering negative return on equity of 287.94% and a negative net margin of 289.75%. It recorded revenue of $43.11 million in the quarter, significantly surpassing the estimated $10.17 million. Analysts are generally forecasting that AnaptysBio will report an EPS of -6.08 for the current fiscal year.

Stock Buyback Program Announcement

In another development, AnaptysBio announced on March 24th that its board approved a stock buyback program, allowing the company to repurchase up to $75 million worth of its outstanding shares. This strategy permits the company to buy back as much as 13.1% of its stock through open market purchases, which often signals that the management believes their shares are currently undervalued.

Insider Transactions

In related news, Director Ecor1 Capital, LLC acquired 6,646 shares of AnaptysBio stock on January 2nd at an average cost of $12.95 per share, amounting to a total investment of $86,065.70. Following this acquisition, the director now holds 7,880,094 shares in the company, valued at approximately $102 million. This transaction represented a slight increase, specifically a 0.08% rise in their ownership. Furthermore, it has been disclosed that corporate insiders currently own 33.70% of AnaptysBio's stock.

Institutional Investor Activities

Numerous hedge funds and institutional investors have been active in buying and selling shares of AnaptysBio. For instance, FMR LLC increased its stake by 15.3% in the third quarter, owning 3,309,175 shares valued at around $110.86 million after acquiring an additional 438,557 shares. Similarly, Frazier Life Sciences Management L.P. grew its holdings by 2.0%, owning 2,209,189 shares worth $74.00 million. Vanguard Group Inc., Fairmount Funds Management LLC, and Boxer Capital Management LLC have also made significant movements in their positions regarding AnaptysBio shares.

About AnaptysBio, Inc.

AnaptysBio, Inc. is a clinical-stage biotechnology company focusing on developing immunology therapeutics. The company's product line includes various innovative treatments aimed at addressing autoimmune and inflammatory diseases. Notable products include Rosnilimab, which targets PD-1+ T cells, and ANB032, a non-depleting antibody that inhibits activated T cell proliferation, among others.

AnaptysBio, Stock, Investment